Müller M, Heicappell R, Habermann F, Kaufmann M, Steiner U, Miller K
Department of Urology, Universitätsklinikum Benjamin Franklin, Freic Universität, Berlin, Germany.
Urol Res. 1997;25(3):187-92. doi: 10.1007/BF00941981.
CD44 is the principal cell surface receptor for hyaluronate. Variant forms of the receptor, produced by alternative splicing, have been found to be associated with tumor progression in a variety of cancers. Based on investigations at the RNA level, it has recently been proposed that expression of CD44 variant V2 was present in urothelial cancer but not in normal urothelium. Since a distinctive marker for urothelial cancer would be extremely useful, frozen sections of normal urothelium and urothelial cancer were examined for expression of standard CD44 and CD44V2. Frozen sections of specimens of 35 patients with transitional cell carcinoma of the bladder, 16 specimens of normal bladder and 5 ureters were examined. Immunohistochemical staining was performed using a polyclonal antibody to CD44V2 (PAB CD44V2), a monoclonal antibody to CD44V2 (MAB CD44V2) and a monoclonal antibody to CD44S (MAB CD44S). CD44V2 and CD44S were also measured in lysates of urine sediments from 21 patients by enzyme-linked immunoabsorbent assay (ELISA). All investigated transitional cell carcinomas expressed CD44V2. There was no differentiation between invasive and noninvasive carcinoma. CD44V2 was also expressed in normal urothelium. Standard CD44 was expressed by the transitional cell carcinoma, normal urothelium, musculature and interstitial tissue. The amount of CD44V2 and CD44S in lysates of urine sediments is not correlated to diagnosis. In contrast to investigations at the RNA level, CD44V2 on the protein level seems not to be a distinctive marker for urothelial cancer. Therefore, CD44V2 will not be a useful diagnostic marker for detection of transitional cell carcinoma.
CD44是透明质酸的主要细胞表面受体。已发现由可变剪接产生的该受体变体形式与多种癌症的肿瘤进展相关。基于RNA水平的研究，最近有人提出CD44变体V2在尿路上皮癌中表达，但在正常尿路上皮中不表达。由于尿路上皮癌的独特标志物将非常有用，因此对正常尿路上皮和尿路上皮癌的冰冻切片进行了标准CD44和CD44V2表达的检测。检查了35例膀胱移行细胞癌患者的标本冰冻切片、16例正常膀胱标本和5例输尿管标本。使用针对CD44V2的多克隆抗体（PAB CD44V2）、针对CD44V2的单克隆抗体（MAB CD44V2）和针对CD44S的单克隆抗体（MAB CD44S）进行免疫组织化学染色。还通过酶联免疫吸附测定（ELISA）测量了21例患者尿沉渣裂解物中的CD44V2和CD44S。所有研究的移行细胞癌均表达CD44V2。浸润性癌和非浸润性癌之间没有差异。CD44V2在正常尿路上皮中也有表达。标准CD44在移行细胞癌、正常尿路上皮、肌肉组织和间质组织中表达。尿沉渣裂解物中CD44V2和CD44S的量与诊断无关。与RNA水平的研究相反，蛋白质水平的CD44V2似乎不是尿路上皮癌的独特标志物。因此，CD44V2不会成为检测移行细胞癌的有用诊断标志物。
